Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Combined Training (Strength and Endurance) and the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men

18 juni 2026 bijgewerkt door: Arya Habibi

Effect of Upper Body and Lower Body Combined Training (Strength and Endurance) on the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men

This randomized controlled trial investigated the effects of upper body-based and lower body-based combined training on serum levels of myostatin (MSTN) and hormone-sensitive lipase (HSL) in overweight and obese men. Myostatin is a myokine involved in the regulation of skeletal muscle growth and adipose tissue metabolism, while HSL is a key enzyme involved in lipolysis and fat mobilization.

Thirty-six overweight and obese men were assigned to either an upper body combined training group, a lower body combined training group, or a non-exercising control group. The intervention consisted of 10 weeks of combined resistance and aerobic training performed three times per week. Serum levels of MSTN and HSL were measured before and after the intervention to determine whether upper body-focused and lower body-focused combined training produce different effects on markers associated with muscle growth and lipid metabolism.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

36

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Tehran Province
      • Tehran, Tehran Province, Iran
        • Faculty of Sports and Health Sciences of the University of Tehran

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Male participants aged 20 to 45 years.
  • Body mass index (BMI) ≥25 kg/m².
  • Overweight or obese status.
  • No participation in regular resistance or aerobic exercise during the previous 6 months.
  • Willingness to participate and provide written informed consent.

Exclusion Criteria:

  • Presence of metabolic diseases, including diabetes mellitus.
  • Presence of cardiovascular or respiratory diseases.
  • Musculoskeletal or joint injuries that could interfere with exercise participation.
  • Use of anti-obesity medications.
  • Use of anabolic steroids, sports supplements, or fat-burning supplements.
  • Regular alcohol consumption or tobacco use.
  • Absence from more than two training sessions during the intervention period.
  • Withdrawal of consent or unwillingness to continue participation.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Upper Body Combined Training
Participants completed a 10-week upper body-focused combined training program three times per week. Each session consisted of upper body resistance exercises followed by aerobic exercise performed on a hand ergometer. Resistance training included chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal exercises.
Participants completed a 10-week upper body-focused combined training program performed three times per week. Each session included six upper body resistance exercises (chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal machine exercises) followed by aerobic exercise on a hand ergometer. Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set. Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week. Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training.
Andere namen:
  • Upper Body Resistance and Aerobic Training
Experimenteel: Lower Body Combined Training
Participants completed a 10-week lower body-focused combined training program three times per week. Each session consisted of lower body resistance exercises followed by aerobic exercise performed on a leg ergometer. Resistance training included leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises.
Participants completed a 10-week lower body-focused combined training program performed three times per week. Each session included six lower body resistance exercises (leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises) followed by aerobic exercise on a leg ergometer. Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set. Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week. Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training.
Andere namen:
  • Lower Body Resistance and Aerobic Training
Geen tussenkomst: Control
Participants in the control group did not participate in the exercise intervention and were instructed to maintain their usual daily activities throughout the 10-week study period.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in serum myostatin (MSTN) concentration
Tijdsspanne: Baseline and 10 weeks
Serum myostatin concentration measured by enzyme-linked immunosorbent assay (ELISA). The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
Baseline and 10 weeks
Change in serum hormone-sensitive lipase (HSL) concentration
Tijdsspanne: Baseline and 10 weeks
Serum hormone-sensitive lipase concentration measured by enzyme-linked immunosorbent assay (ELISA). The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
Baseline and 10 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 mei 2024

Primaire voltooiing (Werkelijk)

1 mei 2024

Studie voltooiing (Werkelijk)

15 december 2024

Studieregistratiedata

Eerst ingediend

14 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 juni 2026

Eerst geplaatst (Werkelijk)

18 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

23 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

18 juni 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data (IPD) will not be made publicly available. The study was not originally designed with a formal data-sharing plan, and participant-level data contain information that could potentially compromise participant confidentiality.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren